Prognostic Significance of Inflammatory Biomarkers in First-Line Immunotherapy for Metastatic Melanoma: Multicentric Study
Authors:
- Branko DujovicBDBranko Dujovic
- Aleksandar PopovicAPAleksandar Popovic
- Amina Jalovcic SuljevicASAmina Jalovcic Suljevic
- Bojana Cikota-AleksicBCBojana Cikota-Aleksic
- Mirjana BalicMBMirjana Balic
- Igor SalaticISIgor Salatic
- Jovana PavlicaJPJovana Pavlica
- Philipp SchneckoPSPhilipp Schnecko
- Tanja MestiTMTanja Mesti
- Muamer TerzoMTMuamer Terzo
- Emina Bicakcic FilipovicEFEmina Bicakcic Filipovic
- Lidija KandolfLKLidija Kandolf
Open Access
Abstract
Background/Objectives: This study evaluates the prognostic value of baseline inflammatory biomarkers, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), and pan-immune-inflammation value (PIV) in advanced cutaneous melanoma treated with first-line immunotherapy. Methods: This multicenter retrospective study included 162 patients with unresectable stage III/IV cutaneous melanoma treated with first-line pembrolizumab, nivolumab, or nivolumab plus ipilimumab. Biomarkers were calculated from complete blood counts obtained within 30 days before treatment start. Cut-offs were defined by ROC analysis. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan–Meier and Cox regression. Response was assessed by RECIST v1.1. Results: Higher baseline NLR, PLR, MLR, SII, and PIV were more common in patients with adverse baseline features, including liver metastases, elevated LDH, and poorer ECOG performance status. Patients with biomarker values below the cut-offs had significantly longer PFS and OS. In biomarker-specific multivariable models adjusted for selected clinical covariates, PIV retained the most consistent association with PFS and OS, while MLR was associated with PFS, and PLR with OS. Conclusions: Baseline inflammatory biomarkers from routine blood counts provide useful prognostic information in advanced melanoma treated with first-line ICIs. PIV showed the most consistent association with survival outcomes and may support initial risk stratification alongside LDH, ECOG, and metastasis pattern. However, prospective validation in independent cohorts is needed before routine clinical implementation.Keywords
All Related Versions
Funding Information
- Science Fund of the Republic of Serbia (6795)
This publication has 38 references indexed in Scilit:
- European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024European Journal of Cancer, 2024
- Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2024
- Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international studyESMO Open, 2024
- The role of platelets in the regulation of tumor growth and metastasis: the mechanisms and targeted therapyMedcomm, 2023
- Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040JAMA Dermatology, 2022
- The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapyJournal of Cancer Research and Clinical Oncology, 2022
- The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line TherapyTargeted Oncology, 2021
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyThe Lancet Oncology, 2019
- Direct Signaling between Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes MetastasisCancer Cell, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009